QIAGEN Q2 Profit Rises to $103.4M, Reaffirms 2026 Outlook
QGEN sits 20% above its 52-week low of $32.53.
Summary
QIAGEN reported Q2 net income of $103.4 million, up from $96.3 million a year ago, with adjusted EPS of $0.62 versus $0.60. Revenue was essentially flat at $535 million, as growth in Sample Technologies and QuantiFERON was offset by declines in Diagnostic Solutions and PCR. The company reaffirmed its full-year 2026 outlook for constant currency sales growth of 1-2% and adjusted EPS of at least $2.43, and provided Q3 guidance in line with that trajectory. This follows a Q1 that saw a 25% drop in net income, so the sequential improvement is notable, though top-line growth remains tepid. The reaffirmed guidance suggests management sees stability, but the flat revenue and mixed segment performance may keep traders cautious.
At the time of this announcement, QGEN was trading at $39.07 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.